Adalta Ltd - Asset Resilience Ratio

Latest as of June 2024: -3.70%

Adalta Ltd (1AD) has an Asset Resilience Ratio of -3.70% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$-206.28K
≈ $-145.96K USD Cash + Short-term Investments

Total Assets

AU$5.57 Million
≈ $3.94 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2024)

This chart shows how Adalta Ltd's Asset Resilience Ratio has changed over time. Check Adalta Ltd (1AD) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Adalta Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Adalta Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$-206.28K -3.7%
Total Liquid Assets AU$-206.28K -3.70%

Asset Resilience Insights

  • Limited Liquidity: Adalta Ltd maintains only -3.70% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Adalta Ltd Industry Peers by Asset Resilience Ratio

Compare Adalta Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Biotechnology 46.79%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 63.47%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for Adalta Ltd (2017–2024)

The table below shows the annual Asset Resilience Ratio data for Adalta Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-06-30 -3.70% AU$-206.28K
≈ $-145.96K
AU$5.57 Million
≈ $3.94 Million
-52.44pp
2020-06-30 48.74% AU$3.37 Million
≈ $2.38 Million
AU$6.91 Million
≈ $4.89 Million
-10.94pp
2019-06-30 59.68% AU$5.56 Million
≈ $3.93 Million
AU$9.31 Million
≈ $6.59 Million
+7.73pp
2018-06-30 51.95% AU$2.31 Million
≈ $1.63 Million
AU$4.44 Million
≈ $3.14 Million
-24.99pp
2017-06-30 76.94% AU$6.22 Million
≈ $4.40 Million
AU$8.09 Million
≈ $5.72 Million
--
pp = percentage points

About Adalta Ltd

AU:1AD Australia Biotechnology
Market Cap
$5.41 Million
AU$7.65 Million AUD
Market Cap Rank
#28387 Global
#1494 in Australia
Share Price
AU$0.00
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.01
All Time High
AU$0.37
About

AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age… Read more